Keytruda: Merck’s Largest Revenue Contributor in 4Q17
Keytruda, the top-selling drug in Merck & Co.’s (MRK) portfolio, was launched in 2014 and is approved for seven indications to date.
The chart below shows Keytruda’s revenues since 1Q15. For 4Q17, Keytruda reported revenues of ~$1.3 billion for 169.0% growth compared to revenues of $483.0 million in 4Q16. This growth includes a 166.0% increase in operating revenues and a 3.0% favorable impact of foreign exchange.
Interested in MRK? Don't miss the next report.
Receive e-mail alerts for new research on MRK
Keytruda is approved for the treatment of seven forms of tumors:
- squamous cell carcinoma of head and neck
- classical Hodgkin lymphoma
- microsatellite instability-high cancer
- advanced non-small cell lung cancer
- advanced melanoma
- advanced Urothelial bladder cancer
- advanced gastric cancer
Keytruda is one of the most important drugs developed by Merck & Co. Keytruda is being evaluated as a monotherapy and a combination drug for the treatment of more than 30 tumor types in more than 500 clinical trials.
On January 19, 2018, Merck & Co. (MRK) released the first-time data for the Keynote-224 study. Keynote-224 is a Phase 2 study investigating the use of Keytruda for the treatment of patients with advanced hepatocellular carcinoma, a type of liver cancer.
Keytruda is approved for the treatment of advanced melanoma. Other drugs approved for the treatment of various forms of melanoma include Genentech’s Cotellic, Amgen’s (AMGN) Imlygic, Bristol-Myers Squibb’s (BMY) Opdivo, and Novartis’s (NVS) Tafinlar and Mekinist combination.